Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines

Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S109-18. doi: 10.1097/INF.0b013e318199f62d.

Abstract

Background: Licensed pneumococcal conjugate vaccine (7vCRM) is usually coadministered with combination vaccines in pediatric immunization programs. Reactogenicity and safety after primary and booster vaccination with a novel 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) in comparison with 7vCRM, both coadministered with commonly used pediatric vaccines, was evaluated in 5 clinical studies.

Methods: Five randomized, controlled studies in which PHiD-CV or licensed 7vCRM vaccines coadministered with various DTPa-based combination vaccines, Neisseria meningitidis serogroup C conjugate vaccines and DTPw-HBV/Hib were conducted. Local and general symptoms were solicited for 4 days after each vaccine dose, using diary cards. All adverse events were recorded for 31 days after each dose and serious adverse events throughout the entire study periods.

Results: A total of 4004 subjects contributed to the safety data analyzed in this review. Fever >or=38.0 degrees C (rectal temperature) was reported after about one-third of primary or booster vaccine doses coadministered with DTPa-based vaccines and after approximately 60% of primary doses with DTPw coadministration in both PHiD-CV and 7vCRM groups. Fever >40.0 degrees C was reported after <or=1.1% of PHiD-CV doses and <or=2.2% of 7vCRM doses. The incidences and intensity of general reactions were generally within the same ranges in the PHiD-CV and 7vCRM groups. Drowsiness and irritability in the study with MenC-conjugates coadministration and irritability and loss of appetite in the study with DTPw-combined vaccines coadministration tended to be slightly higher in PHiD-CV groups. No such trend was observed for solicited general symptoms with grade 3 intensity.

Conclusions: The safety and reactogenicity profiles of PHiD-CV and 7vCRM were within the same range when administered for primary and booster vaccination in coadministration with other routinely used pediatric vaccines.

Trial registration: ClinicalTrials.gov NCT00307554 NCT00334334 NCT00344318 NCT00370396 NCT00463437.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Bacterial Proteins / immunology*
  • Carrier Proteins / immunology*
  • Diphtheria-Tetanus-Pertussis Vaccine
  • Female
  • Haemophilus Vaccines
  • Hepatitis B Vaccines
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Humans
  • Immunization Programs
  • Immunization Schedule
  • Immunization, Secondary
  • Immunoglobulin D / immunology*
  • Infant
  • Lipoproteins / immunology*
  • Male
  • Meningococcal Vaccines / administration & dosage
  • Meningococcal Vaccines / adverse effects*
  • Neisseria meningitidis, Serogroup C
  • Pneumococcal Vaccines / administration & dosage
  • Pneumococcal Vaccines / adverse effects*
  • Poliovirus Vaccine, Inactivated
  • Randomized Controlled Trials as Topic*
  • Treatment Outcome
  • Vaccination
  • Vaccines, Combined / administration & dosage
  • Vaccines, Combined / adverse effects*
  • Vaccines, Conjugate / administration & dosage
  • Vaccines, Conjugate / adverse effects*

Substances

  • Bacterial Proteins
  • Carrier Proteins
  • DTPa-HBV-IPV combined vaccine
  • Diphtheria-Tetanus-Pertussis Vaccine
  • Haemophilus Vaccines
  • Hepatitis B Vaccines
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Immunoglobulin D
  • Lipoproteins
  • Meningococcal Vaccines
  • Pneumococcal Vaccines
  • Poliovirus Vaccine, Inactivated
  • Vaccines, Combined
  • Vaccines, Conjugate
  • glpQ protein, Haemophilus influenzae

Associated data

  • ClinicalTrials.gov/NCT00307554
  • ClinicalTrials.gov/NCT00334334
  • ClinicalTrials.gov/NCT00344318
  • ClinicalTrials.gov/NCT00370396
  • ClinicalTrials.gov/NCT00463437